1. Scrip
  2. >>Therapy Areas
  3. >>Respiratory

Dupixent Shines At ATS, But Experts Question Which Novel Biologic Physicians Will Choose

 
• By Peter Chang

Phase III studies testing Dupixent in moderate-to-severe asthma were largely positive, but subgroup details raise questions about how it will compete against biologics targeting the IL-5 pathway. Some experts urge comparison trials to inform physicians' decisions about long-term use.

Render illustration of Clinical Trial title on medical documents

Regeneron Pharmaceuticals Inc. and Sanofi released positive data for Dupixent (dupilumab) in two studies at the American Thoracic Society (ATS) International Conference in San Diego May 18-23, but despite some differences in profiles, the data don't eliminate questions about which biologic physicians will prefer to treat severe uncontrolled asthma. The data were simultaneously published in the New England Journal of Medicine.

Experts at ATS called for pragmatic comparison trials to help inform the issue down the line. The LIBERTY ASTHMA VENTURE study in patients on oral glucocorticoids (OCS) was reported in a late-breaking session, and LIBERTY ASTHMA QUEST in moderate-to-severe uncontrolled asthma was presented in a poster. Positive top-line numerical data had been released before, though more details from subgroups with lower eosinophil and fraction of exhaled nitric oxide (FeNO) – biomarkers for Type 2 inflammation – were provided at ATS

More from Respiratory

More from Therapy Areas

Sustainability Key To ABL Bio’s Journey From ‘Good To Great’

 
• By Jung Won Shin

Helped by a recent major platform deal with GSK, South Korea's ABL Bio is aiming to build its R&D portfolio with an eye on being acquired in the future. CEO Sang Hoon Lee sat down with Scrip to explain the venture's journey so far and its ambitious roadmap.

Lilly Builds Obesity Momentum With New SURMOUNT Data Besting Novo Nordisk

 
• By Alaric DeArment

The presentation and publication of the Phase IIIb study showing greater efficacy for Zepbound over Wegovy come at a time when competition has been heating up between the two obesity medications.

Chinese Vaccine Makers Turn To Emerging Markets

 
• By Dexter Jie Yan

Chinese producers of novel vaccines are increasingly pivoting to developing markets overseas in the face of a collapse in their domestic sales.